Novo Nordisk to appeal against ruling in repaglinide combination patent case

Today, Novo Nordisk announced that Judge Avern Cohn of the US District Court for the Eastern District of Michigan issued an adverse ruling in a patent litigation case regarding Novo Nordisk's US Patent No. 6,677,358. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable. Novo Nordisk markets repaglinide under the trade name Prandin® and a fixed dose repaglinide/metformin tablet under the trade name PrandiMet®. The district court ruling has the potential to facilitate launch of a generic repaglinide. At present, it is unclear whether or when a generic version of Prandin® or PrandiMet® will be available in the U.S. market. Novo Nordisk intends to appeal this ruling and is evaluating its best options for doing so.

"We are disappointed with today's ruling. We believe that it is contrary to the evidence and we intend to appeal the ruling," says Jesper Brandgaard, executive vice president and chief financial officer of Novo Nordisk.

For the first nine months of 2010, US sales of Prandin® and PrandiMet® amounted to USD 134 million.

Source:

Novo Nordisk

Advertisement

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
New research program receives DKK 100 million in funding from Novo Nordisk Foundation